05/18/2021 | Press release | Distributed by Public on 05/18/2021 05:35
OCALA, Fla., May 18, 2021 - AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the first quarter ended March 31, 2021.
'I'm extremely proud of the progress we have made throughout the first quarter,' commented Thomas K. Equels, CEO of AIM ImmunoTech. 'We have established a strong foundation of pre-clinical and clinical data with respect to the development of therapeutics aimed to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19. With our solid financial standing, we intend to execute on our corporate strategy and aggressively move forward with our clinical programs that address critical unmet medical needs. We have reached many important milestones, are encouraged by the outlook for AIM and look forward to providing meaningful updates along the way.'
Please refer to the full 10-Q for complete details. Additionally, please refer to AIM's most recent Company Presentation for updates on ongoing clinical studies.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of
therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus.
Investor Relations Contact:
Crescendo Communications, LLC
Phone: 212-671-1021
Email: [email protected]
AIM ImmunoTech Inc
Phone: 800-778-4042
Email: [email protected]